Cohera snags $17M to support TissuGlu

By Damian Garde Pittsburgh’s Cohera Medical has closed a $17 million Series D, money the company will use to expand the adoption of its TissuGlu surgical adhesive and support ...

Second Sight scores victory with FDA nod for retinal prosthesis

By Mark Hollmer California’s Second Sight Medical Products has accomplished a major milestone in the U.S., gaining FDA approval for the first-ever retinal implant here designed ...

Health Officials Urge F.D.A. to Limit Sweeteners in Sodas

By STEPHANIE STROM A group of health advocates and public health officials from major cities around the country are asking the Food and Drug Administration to regulate the amount ...

Petition to Delay Biosimilar Game in U.S. Picks up Steam

By Mari Serebrov While other countries are building a strong lineup of biosimilars, the U.S. entry into the game could be delayed until 2022 – if Abbott Laboratories succeeds in making ...

Eylea boosts Regeneron past estimates; Actelion hikes dividend for waiting investors

By Tracy Staton A duo of new earnings announcements from smaller drugmakers offers a microcosmic view of the Big Pharma results we’ve seen so far. Generic competition hurts, ...

Teva’s at-risk Protonix launch could cost $2B-plus

By Tracy Staton Turns out, Teva Pharmaceutical Industries’ ($TEVA) at-risk launch of copycat Protonix was really, really risky. The company now says it’s looking at ...

Medtronic gets FDA nod for next-gen, MRI-friendly pacer

By Mark Hollmer Medtronic ($MDT) gained FDA approval for what will become its second MRI-friendly pacer in the United States, and only the second device of its kind to gain ...

St. Jude recalls heart-plug component as FDA warns of fatal risk

By Damian Garde St. Jude Medical ($STJ) is recalling the device it uses to deploy its Amplatzer PFO Occluder into the heart, warning that the tech can break and put patients at ...

Feds still zealous about off-label marketing, DoJ official says

Caronia free-speech decision won’t affect government probes By Tracy Staton The FDA expected it, and now it’s official: The Justice Department won’t be backing ...

GSK, others weigh $3-4 billion deal for Brazilian drugmaker: sources

By Ben Hirschler and Nadia Damouni (Reuters) – Britain’s GlaxoSmithKline (GSK.L) is one of several groups exploring a potential takeover of Ache Laboratorios Farmaceuticos, ...

Africa is next on Big Pharma’s emerging markets growth curve

By Tracy Staton What’s Big Pharma’s latest frontier? Africa. Yes, drugmakers have been active on the continent for years, primarily in fighting infectious diseases. But ...

Bristol licenses OTC brands to Reckitt for ‘eye-watering’ $482M

By Tracy Staton   Reckitt Benckiser has nabbed Latin American rights to a basket of Bristol-Myers Squibb’s ($BMY) over-the-counter products for a cool $482 million. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS